The relationship between serum brain-derived neurotrophic factor (BDNF) and cardiometabolic indices in schizophrenia

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 244-248

  Nurjono, Milawaty ^a   Tay, Yi Hang ^b   Lee, Jimmy ^a,c  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b MINISTRY OF HEALTH   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Cardiovascular diseases; Framingham risk score; Metabolic indices

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; TRIACYLGLYCEROL; BIOLOGICAL MARKER; CHOLESTEROL; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENERGY METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; YOUNG ADULT; BLOOD; CARDIOVASCULAR DISEASES; CHINA; COMORBIDITY; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARDIOVASCULAR DISEASES; CHINA; CHOLESTEROL; CHOLESTEROL, HDL; COMORBIDITY; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA; TRIGLYCERIDES; YOUNG ADULT;

EID: 84904135268     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.05.024     Document Type: Article

References (44)

1. Amoureux S., Lorgis L., Sicard P., Girard C., Rochette L., Vergely C. Vascular BDNF expression and oxidative stress during aging and the development of chronic hypertension. Fundam. Clin. Pharmacol. 2012, 26(2):227-234.
2. Balaratnasingam S., Janca A. Brain derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol. Ther. 2012, 134(1):116-124.
3. Bobes J., Arango C., Garcia-Garcia M., Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr. Res. 2010, 119(1-3):101-109.
4. Bus B.A.A., Molendijk M.L., Penninx B.J.W.H., Buitelaar J.K., Kenis G., Prickaerts J., Elzinga B.M., Voshaar R.C.O. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011, 36(2):228-239.
5. Camerino C., Zayzafoon M., Rymaszewski M., Heiny J., Rios M., Hauschka P.V. Central depletion of brain-derived neurotrophic factor in mice results in high bone mass and metabolic phenotype. Endocrinology 2012, 153(11):5394-5405.
6. Chaldakov G.N., Fiore M., Stankulov I.S., Manni L., Hristova M.G., Antonelli A., Ghenev P.I., Aloe L. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease?. Progress in Brain Research 2004, 279-289. Elsevier. A. Luigi, C. Laura (Eds.).
7. Crump C., Winkleby M., Sundquist K., Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am. J. Psychiatry 2013, 170(3):324-333.
8. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M., Kannel W.B. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117(6):743-753.
9. Fargali S., Sadahiro M., Jiang C., Frick A., Indall T., Cogliani V., Welagen J., Lin W.-J., Salton S. Role of neurotrophins in the development and function of neural circuits that regulate energy homeostasis. J. Mol. Neurosci. 2012, 48(3):654-659.
10. Favalli G., Li J., Belmonte-de-Abreu P., Wong A.H.C., Daskalakis Z.J. The role of BDNF in the pathophysiology and treatment of schizophrenia. J. Psychiatr. Res. 2012, 46(1):1-11.
11. Fujinami A., Ohta K., Obayashi H., Fukui M., Hasegawa G., Nakamura N., Kozai H., Imai S., Ohta M. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: relationship to glucose metabolism and biomarkers of insulin resistance. Clin. Biochem. 2008, 41(10-11):812-817.
12. Golden E., Emiliano A., Maudsley S., Windham B.G., Carlson O.D., Egan J.M., Driscoll I., Ferrucci L., Martin B., Mattson M.P. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS One 2010, 5(4):e10099.
13. Green M., Matheson S., Shepherd A., Wickert C., Carr V. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta analysis. Mol. Psychiatry 2011, 16(9):960-972.
14. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J. Cardiovasc. Risk 1996, 3(2):213-219.
15. Hristova M.G. Metabolic syndrome - from the neurotrophic hypotheses to a theory. Med Hypotheses 2013, 81(4):627-634.
16. Jiang H., Liu Y., Zhang Y., Chen Z.-Y. Association of plasma brain-derived neurotrophic factor and cardiovascular risk factors and prognosis in angina pectoris. Biochem. Biophys. Res. Commun. 2011, 415(1):99-103.
17. Jiang J., See Y., Subramaniam M., Lee J. Investigation of cigarette smoking among male schizophrenia patients. PLoS One 2013, 8(8):e71343.
18. Jung S., Kim J., Davis J.M., Blair S., Cho H.-c. Association among basal serum BDNF, cardiorespiratory fitness and cardiovascular disease risk factors in untrained healthy Korean men. Eur. J. Appl. Physiol. 2011, 111(2):303-311.
19. Krabbe K.S., Nielsen A.R., Krogh-Madsen R., Plomgaard P., Rasmussen P., Erikstrup C., Fischer C.P., Lindegaard B., Petersen A.M.W., Taudorf S., Secher N.H., Pilegaard H., Bruunsgaard H., Pedersen B.K. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007, 50(2):431-438.
20. Krabbe K.S., Mortensen E.L., Avlund K., Pedersen A.N., Pedersen B.K., Jørgensen T., Bruunsgaard H. Brain-derived neurotrophic factor predicts mortality risk in older women. J. Am. Geriatr. Soc. 2009, 57(8):1447-1452.
21. Kumari V., Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci. Biobehav. Rev. 2005, 29(6):1021-1034.
22. Lee J., Heng D., Ma S., Chew S.-K., Hughes K., Tai E.S. The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin. Endocrinol. 2008, 69(2):225-230.
23. Lee A., Lange C., Roland R., Hellweg R., Lang U. Reduced
24. Lee J., Nurjono M., Wong A., Salim A. Prevalence of Metabolic Syndrome Among Patients with Schizophrenia in Singapore. Ann. Acad. Med. Singap. 2012, 41:457-462.
25. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand. 2009, 119(1):4-14.
26. Mitchell A.J., Vancampfort D., De Herdt A., Yu W., De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr. Bull. 2013, 39(2):295-305.
27. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr. Bull. 2013, 39(2):306-318.
28. Noble E., Billington C., Kotz C.M., Wang C. The lighter side of BDNF. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300(5):R1053-R1069.
29. Nurjono M., Lee J., Chong S. A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clin. Psychopharmacol. Neurosci. 2012, 10(2):61-70.
30. Pikula A., Beiser A.S., Chen T.C., Preis S.R., Vorgias D., DeCarli C., Au R., Kelly-Hayes M., Kase C.S., Wolf P.A., Vasan R.S., Seshadri S. Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham study. Stroke 2013, 44(10):2768-2775.
31. Pillai A., Kale A., Joshi S., Naphade N., Raju M.S.V.K., Nasrallah H., Mahadik S.P. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int. J. Neuropsychopharmacol. 2010, 13(04):535-539.
32. Rosas-Vargas H., Martínez-Ezquerro J.D., Bienvenu T. Brain-derived neurotrophic factor, food intake regulation, and obesity. Arch. Med. Res. 2011, 42(6):482-494.
33. Rothman S., Griffioen K., Wan R., Mattson M. Brain-derived neurotrophic factor as a regulator of systemic and brain energy metabolism and cardiovascular health. Ann. N. Y. Acad. Sci. 2012, 1264:49-63.
34. Rothman S.M., Griffioen K.J., Wan R., Mattson M.P. Brain-derived neurotrophic factor as a regulator of systemic and brain energy metabolism and cardiovascular health. Ann. N. Y. Acad. Sci. 2012, 1264(1):49-63.
35. Tang S., Machaalani R., Waters K.A. Immunolocalization of pro- and mature-brain derived neurotrophic factor (BDNF) and receptor TrkB in the human brainstem and hippocampus. Brain Res. 2010, 1354:1-14.
36. Tay Y.H., Nurjono M., Lee J. Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. Schizophr. Res. 2013, 147(1):187-192.
37. Thompson R., Wickert C., Wyatt E., MJ W. Decreased BDNF, trkB-TK+and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatr. Neurosci. 2011, 36(3):195-203.
38. van den Hoogen P.C.W., Feskens E.J.M., Nagelkerke N.J.D., Menotti A., Nissinen A., Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N. Engl. J. Med. 2000, 342(1):1-8.
39. Vasic N., Connemann B., Wolf R., Tumani H., Brettschneider J. Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262(5):375-391.
40. Wang H., Zhou X.F. Injection of brain-derived neurotrophic factor in the rostral ventrolateral medulla increases arterial blood pressure in anaesthetized rats. Neuroscience 2002, 112(4):967-975.
41. Wehring H.J., Liu F., McMahon R.P., Mackowick K.M., Love R.C., Dixon L., Kelly D.L. Clinical characteristics of heavy and non-heavy smokers with schizophrenia. Schizophr. Res. 2012, 138(2-3):285-289.
42. Willett W., Hennekens C.H., Castelli W., Rosner B., Evans D., Taylor J., Kass E.H. Effects of cigarette smoking on fasting triglyceride, total cholesterol, and HDL-cholesterol in women. Am. Heart J. 1983, 105(3):417-421.
43. Winterer G. Why do patients with schizophrenia smoke?. Curr. Opin. Psychiatr. 2010, 23:112-119.
44. Zhang X., Xiu M., Chen D., Yang F., Wu G., Lu L., Kosten T., Kosten T. Nicotine dependence and serum BDNF levels in male patients with schizophrenia. Psychopharmacology 2010, 212(3):301-307.